CA2247246A1 - Compositions et procedes de traitement et de diagnostic des maladies cardio-vasculaires - Google Patents

Compositions et procedes de traitement et de diagnostic des maladies cardio-vasculaires Download PDF

Info

Publication number
CA2247246A1
CA2247246A1 CA002247246A CA2247246A CA2247246A1 CA 2247246 A1 CA2247246 A1 CA 2247246A1 CA 002247246 A CA002247246 A CA 002247246A CA 2247246 A CA2247246 A CA 2247246A CA 2247246 A1 CA2247246 A1 CA 2247246A1
Authority
CA
Canada
Prior art keywords
gene
protein
cardiovascular disease
expression
genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002247246A
Other languages
English (en)
Inventor
Dean A. Falb
Michael A. Gimbrone, Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Millennium Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26682786&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2247246(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2247246A1 publication Critical patent/CA2247246A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention se rapporte à des procédés et à des compositions de traitement et de diagnotic de maladies cardio-vasculaires comprenant, mais pas exclusivement, l'athérosclérose, l'ischémie/reperfusion, l'hypertension, la resténose et l'inflammation artérielle. Dans cette invention on identifie et décrit notamment des gènes qui sont exprimés de manière différentielle dans des états pathologiques cardio-vasculaires, par rapport à leur expression dans des états pathologiques normaux ou non cardio-vasculaires, et/ou en réponse à des manipulations appropriées aux maladies cardio-vasculaires. En outre, dans cette invention on identifie et décrit des gènes par le biais de la capacité de leurs produits géniques à interagir avec les produits géniques impliqués dans les maladies cardio-vasculaires. L'invention se rapporte encore à des procédés d'identification et d'utilisation thérapeutique de composés dans les traitements des maladies cardio-vasculaires, des procédés de contrôle diagnostique de patients subissant des bilans cliniques en vue de traiter la maladie cardio-vasculaire, et à des procédés de contrôle de l'efficacité de ces composés dans les essais cliniques. L'invention se rapporte enfin à des procédés d'évaluation diagnostique et de pronostic de diverses maladies cardio-vasculaires, ainsi qu'à des procédés d'identification de sujets présentant une prédisposition à ces états.
CA002247246A 1996-02-16 1997-02-14 Compositions et procedes de traitement et de diagnostic des maladies cardio-vasculaires Abandoned CA2247246A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US1178796P 1996-02-16 1996-02-16
US60/011,787 1996-02-16
US79991097A 1997-02-13 1997-02-13
US08/799,910 1997-02-13

Publications (1)

Publication Number Publication Date
CA2247246A1 true CA2247246A1 (fr) 1997-08-21

Family

ID=26682786

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002247246A Abandoned CA2247246A1 (fr) 1996-02-16 1997-02-14 Compositions et procedes de traitement et de diagnostic des maladies cardio-vasculaires

Country Status (6)

Country Link
US (7) US6759210B1 (fr)
EP (1) EP0904277A4 (fr)
JP (1) JP2001521365A (fr)
AU (1) AU725192B2 (fr)
CA (1) CA2247246A1 (fr)
WO (1) WO1997030065A1 (fr)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6099823A (en) * 1996-02-16 2000-08-08 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of cardiovascular disease
JPH10295381A (ja) * 1997-04-23 1998-11-10 Seibutsu Bunshi Kogaku Kenkyusho:Kk 新規シグナル伝達因子、およびそれをコードする遺伝子
WO1998053068A1 (fr) * 1997-05-20 1998-11-26 Ludwig Institute For Cancer Research La smad7 et ses utilisations
AU749465B2 (en) 1997-06-13 2002-06-27 Japanese Foundation For Cancer Research Smad6 and uses thereof
US6576478B1 (en) 1998-07-14 2003-06-10 Zyomyx, Inc. Microdevices for high-throughput screening of biomolecules
US6682942B1 (en) 1998-07-14 2004-01-27 Zyomyx, Inc. Microdevices for screening biomolecules
GB9827430D0 (en) * 1998-12-11 1999-02-03 Ludwig Inst Cancer Res Differential expression in primary breast cancer
US20030009013A1 (en) * 1998-12-30 2003-01-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20040248170A1 (en) * 1999-01-06 2004-12-09 Chondrogene Limited Method for the detection of hyperlipidemia related gene transcripts in blood
CA2702148C (fr) * 1999-01-06 2014-03-04 Genenews Inc. Methode de profilage de l'expression genique d'un sujet humain atteint d'une maladie infectieuse
US20040248169A1 (en) * 1999-01-06 2004-12-09 Chondrogene Limited Method for the detection of obesity related gene transcripts in blood
US20050003394A1 (en) * 1999-01-06 2005-01-06 Chondrogene Limited Method for the detection of rheumatoid arthritis related gene transcripts in blood
US20060134635A1 (en) * 2001-02-28 2006-06-22 Chondrogene Limited Method for the detection of coronary artery disease related gene transcripts in blood
US20040265868A1 (en) * 1999-01-06 2004-12-30 Chondrogene Limited Method for the detection of depression related gene transcripts in blood
US20050123938A1 (en) * 1999-01-06 2005-06-09 Chondrogene Limited Method for the detection of osteoarthritis related gene transcripts in blood
US7473528B2 (en) * 1999-01-06 2009-01-06 Genenews Inc. Method for the detection of Chagas disease related gene transcripts in blood
US20070105121A1 (en) * 1999-01-06 2007-05-10 Chondrogene Limited Method for the detection of schizophrenia related gene transcripts in blood
US20040241726A1 (en) * 1999-01-06 2004-12-02 Chondrogene Limited Method for the detection of allergies related gene transcripts in blood
US20040241728A1 (en) * 1999-01-06 2004-12-02 Chondrogene Limited Method for the detection of lung disease related gene transcripts in blood
CA2363496A1 (fr) * 1999-03-16 2000-09-21 Mitokor Expression differentielle de produits geniques d'organites
WO2001004290A1 (fr) * 1999-07-09 2001-01-18 Shanghai Institute Of Biochemistry Oligonucleotides formant une triple helice et leur utilisation en therapie
AU7452300A (en) * 1999-10-01 2001-05-10 Kyowa Hakko Kogyo Co. Ltd. Shear stress-response dna
CA2389751A1 (fr) * 1999-11-01 2001-05-10 Curagen Corporation Genes exprimes de maniere differentielle impliques dans l'angiogenese, polypeptides codes par lesdits genes, et techniques d'utilisation de ces genes
US7423127B2 (en) 1999-12-09 2008-09-09 Genentech, Inc. Antibodies to a polypeptide encoded by a nucleic acid overexpressed in melanoma
US20060160186A1 (en) * 1999-12-09 2006-07-20 Eaton Dan L Nucleic acid underexpressed in stomach tumor and lung tumor
US6159697A (en) * 2000-01-19 2000-12-12 Isis Pharmaceuticals, Inc. Antisense modulation of Smad7 expression
EP1250431A4 (fr) * 2000-01-25 2004-08-11 Digital Gene Tech Inc Modulation de l'expression genique dans la formation de lesions atherosclereuses grasses
US7125660B2 (en) * 2000-09-13 2006-10-24 Archemix Corp. Nucleic acid sensor molecules and methods of using same
EP1334113A4 (fr) * 2000-10-20 2007-08-08 Expression Diagnostics Inc Evaluation du niveau d'expression leucocytaire
WO2002095061A1 (fr) * 2001-05-18 2002-11-28 New York University Procede de criblage de substances test destinees a traiter ou prevenir des maladies impliquant un stress oxydatif
US7026121B1 (en) 2001-06-08 2006-04-11 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US7235358B2 (en) 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US20030013208A1 (en) * 2001-07-13 2003-01-16 Milagen, Inc. Information enhanced antibody arrays
EP1456380B1 (fr) * 2001-11-02 2012-04-18 Giuliani International Limited Inhibiteurs smad7 utilises dans le traitement de maladies cns
US20040067544A1 (en) * 2002-06-27 2004-04-08 Viola Vogel Use of adhesion molecules as bond stress-enhanced nanoscale binding switches
US20040147428A1 (en) * 2002-11-15 2004-07-29 Pluenneke John D. Methods of treatment using an inhibitor of epidermal growth factor receptor
US20040110241A1 (en) * 2002-12-06 2004-06-10 Segal Mark S. Materials and methods for monitoring vascular endothelial function
US20050015048A1 (en) * 2003-03-12 2005-01-20 Chiu Jessica G. Infusion treatment agents, catheters, filter devices, and occlusion devices, and use thereof
US7250041B2 (en) * 2003-03-12 2007-07-31 Abbott Cardiovascular Systems Inc. Retrograde pressure regulated infusion
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
JP2007534611A (ja) * 2003-04-08 2007-11-29 ジェノバ・リミテッド 心臓血管障害に関連する分泌ポリペプチド種
WO2004093892A2 (fr) 2003-04-16 2004-11-04 Genentech, Inc. Procedes et compositions de modulation selective de vascularisation
US20070248978A1 (en) * 2006-04-07 2007-10-25 Expression Diagnostics, Inc. Steroid responsive nucleic acid expression and prediction of disease activity
US7892745B2 (en) 2003-04-24 2011-02-22 Xdx, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
WO2006029184A2 (fr) * 2004-09-08 2006-03-16 Expression Diagnostics, Inc. Genes permettant de diagnostiquer et de surveiller les troubles associes a l'inflammation
EP1885889A4 (fr) * 2005-05-11 2010-01-20 Expression Diagnostics Inc Procedes de surveillance de l'etat fonctionnel de transplants a l'aide de panels de genes
WO2007127908A2 (fr) * 2006-04-28 2007-11-08 Hutchison Medipharma Enterprises Limited Dihydrobenzoquinones
WO2008021431A2 (fr) * 2006-08-14 2008-02-21 Xdx, Inc. Méthodes et compositions permettant de diagnostiquer et de surveiller l'état de rejet de greffe et de troubles immunitaires
EP2102367A2 (fr) * 2006-11-09 2009-09-23 XDX, Inc. Procedes pour diagnostiquer et surveiller l'etat d'un lupus erythemateux systemique
US20100185156A1 (en) * 2007-06-13 2010-07-22 Pervasis Therapeutics, Inc. Methods and Devices for Minimally-Invasive Delivery of Cell-Containing Flowable Compositions
US20110190251A1 (en) * 2008-03-03 2011-08-04 Kepley Christopher L Method for inhibiting the build-up of arterial plaque by administering fullerenes
RU2430683C1 (ru) * 2010-02-01 2011-10-10 Учреждение Российской академии медицинских наук Научный центр проблем здоровья семьи и репродукции человека Сибирского отделения РАМН Способ прогнозирования риска развития эссенциальной артериальной гипертензии у мальчиков подросткового возраста
WO2012065059A2 (fr) * 2010-11-12 2012-05-18 The General Hospital Corporation Traitement de l'athérosclérose par des antagonistes de bmp-alk3

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3854872D1 (de) 1987-03-14 1996-02-22 Boehringer Ingelheim Int Humane Mangan-Superoxiddismutase (hMn-SOD)
US5225326A (en) * 1988-08-31 1993-07-06 Research Development Foundation One step in situ hybridization assay
AU642501B2 (en) 1990-04-30 1993-10-21 Board Of Regents, The University Of Texas System Steroid 5alpha-reductases
US5202420A (en) 1990-10-25 1993-04-13 The Children's Hospital Of Philadelphia Tracheal antimicrobial peptides, dna sequences and methods for the production and use thereof
EP0570496A4 (en) * 1991-01-15 1996-06-12 Genmark Polymorphic dna markers in bovidae
US5424187A (en) * 1991-06-14 1995-06-13 Board Of Regents Of The University Of Washington Method of screening for arterial chlamydial granuloma
EP0593580A4 (en) * 1991-06-20 1995-12-06 Us Health Sequences characteristic of human gene transcription product
US5578444A (en) * 1991-06-27 1996-11-26 Genelabs Technologies, Inc. Sequence-directed DNA-binding molecules compositions and methods
US5418162A (en) * 1991-10-22 1995-05-23 Duke University Serotonin transporter CDNA
US5262311A (en) 1992-03-11 1993-11-16 Dana-Farber Cancer Institute, Inc. Methods to clone polyA mRNA
WO1994003599A1 (fr) * 1992-08-04 1994-02-17 Sagami Chemical Research Center ADNc HUMAIN ET PROTEINE POUR LAQUELLE CODE CET ADNc
US5847007A (en) 1993-05-13 1998-12-08 Neorx Corporation Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
US5624803A (en) * 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
JPH07291996A (ja) 1994-03-01 1995-11-07 Yuu Honshiyo ヒトにおけるプログラムされた細胞死に関連したポリペプチド、それをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞、そのポリペプチドの抗体、およびそのポリペプチドまたはその抗体を含有する薬学的組成物
US5559009A (en) 1994-03-04 1996-09-24 The Regents Of The University Of California Voltage-gated potassium channel gene, KV1.7, vectors and host cells comprising the same, and recombinant methods of making potassium channel proteins
US5834248A (en) 1995-02-10 1998-11-10 Millennium Pharmaceuticals Inc. Compositions and methods using rchd534, a gene uregulated by shear stress
US5834188A (en) * 1995-07-26 1998-11-10 Creative Biomolecule, Inc. Methods and compositions for identifying morphogen analogs
US5780235A (en) * 1996-10-04 1998-07-14 Incyte Pharmaceuticals, Inc. Human voltage-dependent anion channel
US5948639A (en) * 1997-04-10 1999-09-07 Millennium Pharmaceuticals, Inc. TGF-β pathway genes

Also Published As

Publication number Publication date
US6492126B2 (en) 2002-12-10
AU2124397A (en) 1997-09-02
EP0904277A4 (fr) 2003-01-22
US6759210B1 (en) 2004-07-06
JP2001521365A (ja) 2001-11-06
US6534641B2 (en) 2003-03-18
US6087477A (en) 2000-07-11
US6221628B1 (en) 2001-04-24
US20020016303A1 (en) 2002-02-07
US20020034736A1 (en) 2002-03-21
WO1997030065A1 (fr) 1997-08-21
EP0904277A1 (fr) 1999-03-31
AU725192B2 (en) 2000-10-05
US6048709A (en) 2000-04-11
US20020102603A1 (en) 2002-08-01

Similar Documents

Publication Publication Date Title
US6492126B2 (en) Compositions and methods for the treatment and diagnosis of cardiovascular disease
WO1997030065A9 (fr) Compositions et procedes de traitement et de diagnostic des maladies cardio-vasculaires
AU714778B2 (en) Compositions and methods for the treatment and diagnosis of cardiovascular disease
US6099823A (en) Compositions and methods for the treatment and diagnosis of cardiovascular disease
US5853975A (en) Methods for identifying compositions for the treatment of body weight disorders, including obesity
US20020115140A1 (en) Rath genes and polypeptides and methods for the treatment and diagnosis of immune disorders
US6359194B1 (en) Compositions and methods for the treatment and diagnosis of cardiovascular disease
US5846780A (en) Murine RATH gene
US20020142441A1 (en) Compositions and methods for the treatment and diagnosis of cardiovascular disease
US20020170077A1 (en) Compositions and methods for the treatment and diagnosis of cardiovascular disease
WO1998005969A1 (fr) Gene fxi-t1 de mammifere incluant l'homme
MXPA01001048A (en) Compositions and methods for the treatment and diagnosis of cardiovascular disease

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 20040216